NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Prostate Cancer Clinical Trial

Official title:

Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00199849
• Other study ID #: 2005-0013
• Secondary ID: LUD2002-006
• Status: Completed
• Phase: Phase 1
• Start date: September 27, 2004
• Est. completion date: September 2007

Study information

• Verified date: October 2022
• Source: Ludwig Institute for Cancer Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.

Description:

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device. The 4 microgram dosage of NY-ESO-1 was administered as 4 X 1 microgram PMEDs in close proximity. Similarly, the 8 microgram dosage was administered as 8 X 1 microgram PMEDs. The third cohort of patients received the 8 microgram dosage as a cluster dosage of 4 doses (day 1, 3, 5, 8) as 2 X 1 microgram PMEDs per day.

Blood samples were to be obtained at baseline, 2 weeks after each vaccination, prior to the second and third vaccination, and 4 weeks after the third vaccination for the assessment of clinical hematology, biochemistry measurements and immunology responses. Patients were to be evaluated for toxicity throughout the study.

Delayed-type hypersensitivity (DTH) testing was to be performed at baseline and at the 2-week visit following the first and third vaccinations.

NY-ESO-1 and/or LAGE-1 specific antibodies were to be assessed in all patients by an enzyme-linked immunosorbent assay (ELISA). NY-ESO-1 specific CD4+ and CD8+ T-cells were to be assessed in all patients by tetramer and/or ELISPOT assays.

Disease status was to be assessed at baseline and 4 weeks after the third vaccination in patients with measurable disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: September 2007
• Est. primary completion date: September 11, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients were eligible for enrollment if they fulfilled all of the following criteria:

1. Histologically proven tumor type known to express NY-ESO-1 or LAGE-1 (prostate cancer, breast cancer, bladder cancer, hepatocellular cancer, synovial sarcoma, leiomyosarcoma, head and neck, lung cancer, esophageal, ovarian, neuroblastoma); or NY-ESO-1 or LAGE-1 positive tumors determined by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis, preferably, or immunohistochemistry or expression of LAGE-1 by RT-PCR.

2. Advanced disease and have declined, delayed, failed or completed standard therapy.

3. Full recovery from surgery.

4. Expected survival of at least 6 months.

5. Karnofsky performance scale = 60.

6. Adequate bone marrow, kidney, liver and immune functions.

7. Able and willing to give valid written informed consent.

Exclusion Criteria:

1. Clinically significant heart disease (NYHA Class III or IV).

2. Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding disorders, clinically significant liver or renal insufficiency requiring treatment.

3. Patients with serious intercurrent illness, requiring hospitalization.

4. Known HIV, Hepatitis B or Hepatitis C positivity.

5. History of autoimmune diseases (e.g. SLE, scleroderma). Vitiligo is not an exclusion criterion.

6. Concomitant systemic treatment with corticosteroids, anti-histaminic drugs or non-steroidal anti-inflammatory drugs. Specific COX-2 inhibitors are permitted. Low dose aspirin is permitted. Topical or inhalational steroids are permitted.

7. Evidence of skin disease (e.g. psoriasis, eczema or keloid formation) at the proposed administration site.

8. Allergy to gold (including gold jewelry).

9. History or evidence of chrysotherapy (gold salts).

10. Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing (6 weeks for nitrosoureas).

11. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer, cervical carcinoma in situ.

12. Mental impairment, in the opinion of the investigator, that may compromise the ability to give informed consent and comply with the requirements of the study.

13. Lack of availability for immunological and clinical follow-up assessments.

14. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing.

15. Pregnancy or breastfeeding.

16. Women of childbearing potential: Refusal or inability to use effective means of contraception.

Related Conditions & MeSH terms

• Bladder Cancer
• Esophageal Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer
• Sarcoma

Intervention

Biological:
• NY-ESO-1 Plasmid DNA Cancer Vaccine
NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.

Locations

Country	Name	City	State
United States	UT MD Anderson Cancer Center	Houston	Texas
United States	New York Presbyterian Hospital	New York	New York

Sponsors (4)

Lead Sponsor	Collaborator
Ludwig Institute for Cancer Research	M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, New York Presbyterian Hospital

Country where clinical trial is conducted

United States, 

References & Publications (1)

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Dose Limiting Toxicities (DLTs) and Number of Patients With Adverse Events	All adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (CTC) Scale (Version 3.0, published June 10, 2003).; DLT was defined as; = Grade 2 autoimmune phenomena; Asymptomatic bronchospasm or generalized urticaria; Grade = non hematological toxicities (including injection site reactions); Grade = 3 hematological toxicities; A dose-limiting adverse event must be definitely, probably, or possibly related to the administration of the investigational agent and must occur between first dose and 4 weeks after the last dose.	up to 13 weeks
Secondary	Number of Patients With Tumor Response According to the Response Evaluation Criteria in Solid Tumors (RECIST).	Tumor response was assessed in patients with measurable tumors according to the Response Evaluation Criteria in Solid Tumors (RECIST).; Computed tomography (CT) scans were performed at screening and at week 13. Response was assessed using RECIST version 1.0 (Therasse et al, J Natl Cancer Inst 2000; 92:205-16). Per RECIST, target lesions are categorized as follows: complete response (CR): disappearance of all target lesions (no evaluable disease); partial response (PR): = 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD): = 20% increase in the sum of the longest diameter of target lesions; stable disease (SD): small changes that do not meet above criteria; no evidence of disease (NED): no new lesions in patients who did not have target lesions at baseline.	13 weeks
Secondary	Number of Patients With NY-ESO-1-Specific Humoral Immunity as Determined by an Increase in Antibody Titer From Baseline.	Blood samples were obtained at baseline (prior to the first dose), and in weeks 3, 5, 7, 9, 11 and 13 for the assessment of NY-ESO-1-specific antibodies by an enzyme-linked immunosorbent assay (ELISA). A positive response was a readable optical density at 280 nm.	up to 13 weeks
Secondary	Number of Patients With NY-ESO-1-Specific Cellular Immunity as Measured by an Increase in NY-ESO-1-Specific CD4+ and CD8+ T-Cells Following Treatment.	Blood samples were obtained at baseline (prior to the first dose), and in weeks 3, 5, 7, 9, 11 and 13 for the assessment of NY-ESO-1-specific CD4+ and CD8+ T-cell responses by ELISPOT.	up to 13 weeks
Secondary	Number of Patients With Delayed-Type Hypersensitivity (DTH) Skin Reactions to NY-ESO-1 Protein	Delayed-Type Hypersensitivity (DTH) testing was conducted at baseline and on days 15 and 72 of the study. A positive DTH reaction to NY-ESO-1 protein at baseline was absent in all patients. The presence of redness and induration was considered necessary for a positive DTH reaction.	Up to 11 weeks